Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?
复制标题
DOI：
10.1016/j.jsat.2010.01.012
复制
发表时间：
2010-06
影响因子：
3.9
通讯作者：
Woody G
中科院分区：
文献类型：
--
作者：
Nunes EV;Ball S;Booth R;Brigham G;Calsyn DA;Carroll K;Feaster DJ;Hien D;Hubbard RL;Ling W;Petry NM;Rotrosen J;Selzer J;Stitzer M;Tross S;Wakim P;Winhusen T;Woody G
国家药物滥用治疗临床试验网络（CTN）等多中心有效性试验是开发和传播循证治疗的关键一步，因为它们解决了此类治疗在现实世界临床环境中的表现。正如Brigham及其同事在最近的一篇文章中所总结的那样，可以选择几种可能的实验设计来进行这种有效性试验。其中包括：1）将新的治疗干预（Tx）与现有的基于社区的常规治疗（TAU）模式进行比较：Tx与TAU; 2）将新的干预添加到TAU并与单独的TAU进行比较：Tx + TAU与TAU;或3）将新的干预添加到TAU并与添加到TAU的对照条件进行比较：Tx + TAU与对照+ TAU。这些设计中的每一个都解决了不同的问题，并具有不同的潜在优势和劣势。截至2009年12月，在CTN进行的16项多中心随机临床试验的主要结局论文已经发表，这些试验测试了药物滥用、HIV风险行为或相关问题的各种治疗方法。本文系统地检查，为每个已完成的试验，实验设计类型选择和其最初的理由，试验的主要结果，并在事后的优势和劣势的设计。基于这一审查，产生的建议，以告知未来的药物滥用，艾滋病毒的风险和其他行为健康问题的治疗效果试验的设计。
Multi-site effectiveness trials such as those carried out in the National Drug Abuse Treatment Clinical Trials Network (CTN) are a critical step in the development and dissemination of evidence-based treatments, because they address how such treatments perform in real-world clinical settings. As Brigham and colleagues summarized in a recent article, several possible experimental designs may be chosen for such effectiveness trials. These include: 1) A new treatment intervention (Tx) is compared to an existing mode of community based treatment as usual (TAU): Tx versus TAU; 2) A new intervention is added to TAU and compared to TAU alone: Tx + TAU versus TAU; or 3) A new intervention is added to TAU and compared to a control condition added to TAU: Tx + TAU versus control + TAU. Each of these designs addresses a different question and has different potential strengths and weaknesses. As of December 2009, the primary outcome paper had been published for 16 of the multi-site randomized clinical trials conducted in the CTN, testing various treatments for drug abuse, HIV risk behavior, or related problems. This paper systematically examines, for each of the completed trials, the experimental design type chosen and its original rationale, the main findings of the trial, and the strengths and weaknesses of the design in hindsight. Based on this review, recommendations are generated to inform the design of future effectiveness trials on treatments for substance abuse, HIV risk, and other behavioral health problems.
登录
查看更多内容
影响因子：
3.4
作者：
Campbell, Barbara K.;Fuller, Bret E.;McCarty, Dennis
通讯作者：
McCarty, Dennis
DOI：
10.1191/1740774504cn041oa
发表时间：
2004-01-01
期刊：
Clinical trials (London, England)
影响因子：
--
作者：
Feaster, Daniel J;Robbins, Michael S;Szapocznik, Jose
通讯作者：
Szapocznik, Jose
影响因子：
17.7
作者：
Hien, Denise A.;Jiang, Huiping;Nunes, Edward V.
通讯作者：
Nunes, Edward V.
影响因子：
3.7
作者：
Jones, HE;Svikis, D;Kulstad, JL
通讯作者：
Kulstad, JL
影响因子：
4.2
作者：
Carroll, KM;Ball, SA;Woody, GE
通讯作者：
Woody, GE